AstriVax
Committed to address
real-world challenges
in vaccinology
Discover AstriVax
AstriVax is a clinical stage biopharmaceutical company founded in 2022 and focused on developing DNA-based vaccines through a novel technology platform. Our technology aims to address the most challenging diseases, with a primary focus on treating Hepatitis B, Human Papilloma virus and other emerging viral infectious diseases.
First in class Plug & Play vaccine platform
Patented DNA-based technology that launches self-amplifying live attenuated viral vector and antigens of interest
Vaccines that elicit a polyfunctional and vigorous immune response
Wide range of potential use in prophylactic and therapeutic settings
